LONDON, July 2 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines looks set to continue after London's High Court gave a mixed ruling on two of Moderna's patents ...
Our mission is to deliver unbiased, fact-based reporting that holds power to account and exposes the truth. Whether $5 or $50, every contribution counts. A legal battle between rival developers of ...
Moderna Inc. scored a partial victory in its attempt to claim a share of billions of dollars in profits made by Pfizer Inc and BioNTech SE selling Covid-19 vaccine, after a London judge ruled that ...
The London ruling arrives at a challenging time for Moderna, whose shares have dropped over 70% since the pandemic's peak. All three companies expressed disagreement with the parts of the decision ...
Moderna (NASDAQ:MRNA) on Tuesday announced a $176M contract from the U.S. government to accelerate the development of messenger-RNA-based vaccines targeting several influenza strains, including ...
Moderna's success with COVID-19 vaccine approval under Operation Warp Speed led to a temporary revenue surge, but future sales may be limited due to politicization of vaccines and competition.
Moderna stock tumbled in late June after unveiling updated test results for its RSV vaccine. Is MRNA stock now a sell? Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry ...
Moderna is set to receive $176 million in federal funding to develop a human vaccine against bird flu following outbreaks of the virus in dairy cows across several states, the Department of Health ...
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low. Moderna says its updated coronavirus ...